Self-Assessment: Novel Therapeutic Approaches for ALS: From Bench to Bedside

Self-Assessment: Novel Therapeutic Approaches for ALS: From Bench to Bedside | Selected Topics on MG

From 2023 Annual Meeting session content.

Course Description

This self-assessment course is created from two sessions held at the 2023 Annual Meeting.

Novel Therapeutic Approaches for ALS: From Bench to Bedside
Recognize the expectation and unmet needs for ALS treatment; discuss the preclinical data in ALS supporting novel therapeutic approaches, existing data on trials, and the challenges and opportunities for these approaches; and explain recent progress in trial designs and pharmacological therapies. Novel therapeutics and improving study design will be discussed including use of antisense oligonucleotides for familial ALS, cell therapy, recently approved drugs (Relyvrio and edaravone), and drugs under development. Review recently completed and ongoing clinical trials for familial ALS focusing on ASOs for SOD1, FUS, C9, ATXN-2; lessons from observational trials for presymptomatic gene carriers (PreFALS study, PREVENT ALS study which is the merger of DIALS at MGH/WashU and ALS Families at Columbia, ALL-FTD) and how these our inform knowledge of presymptomatic/prodromal ALS; and discuss movement towards preventative therapies for familial ALS (ATLAS trial of tofersen).

Selected Topics on MG
Summarize how to discuss with myasthenic patients general care topics such as proper nutrition, exercise, infection control, immunization, and preparation for surgery; recognize medication influence on MG; review how to avoid medication induced exacerbation; and discuss how to diagnose and manage myasthenic crisis.

Objectives:
1. Recognize the expectation and unmet needs for ALS treatment, including identifying the limitations of current therapeutic approaches.
2. Identify the challenges and opportunities associated with novel therapeutic approaches for ALS, including factors such as drug development and patient care.
3. Summarize essential care topics for myasthenic patients, including proper nutrition, exercise, infection control, immunization, and preparation for surgery.
4. Discuss the diagnosis and management of myasthenic crisis, including the identification of warning signs, appropriate interventions, and critical care considerations for severe MG cases.

To claim self-assessment (SA) credit, you must watch the session recordings and answer a post-test. You must get above a 70% on the post-test survey to claim credit.

The American Board of Psychiatry and Neurology (ABPN) and the American Board of Physical Medicine and Rehabilitation (ABPMR) have reviewed and approved this product as part of a comprehensive lifelong learning program, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of maintenance of certification (MOC).

ACCREDITATION STATEMENT : The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION :
The AANEM designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits ^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit expires 11/1/2026.

Summary


Availability:	On-Demand
	Expires on Nov 01, 2026


Cost:	Member: $50.00 Non-Member: $75.00


Credit Offered:	3 SA CME Credits 3 CEU Credits